Development and validation of a model for predicting the adult height of girls with idiopathic central precocious puberty

Wu, Wenyong; Zhu, Xiaoyun; Chen, Yun; Yang, Xiaohong; Zhang, Ying; Chen, Ruimin

doi:10.1007/s00431-023-04842-3

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it was arguable whether the gain was the result of medication or the spurious effect of confounding factors due to the inconsistent baseline. For more reliable results, GLM was adopted to control the impacts on outcomes from confounders that were determined mainly based on previous studies [21,[24][25][26], results of baseline analysis, and clinical experience. The adjusted results revealed that the final height, height gain, genetic height gain, FHSDS and HSDS gain of patients receiving GnRHa combined with rhGH were significantly better than those receiving GnRHa alone and no treatment, which meant that the combination therapy could improve the final height of girls with CPP or EP to some extent, narrow the gap of height with the normal peer, and provide significant benefits compared with PAH, TH and HSDS before intervention.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of pharmacotherapy for girls with central precocious puberty or early puberty: a retrospective cohort study

Yang,

Huang,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: The use of recombinant human growth hormone (rhGH) for central precocious puberty (CPP) and early puberty (EP) is off-label and lacks reliable evidence for clinical practice. This study aimed to compare the long-term efficacy and safety of gonadotrophin releasing hormone analogue (GnRHa) in combination with or without rhGH for the treatment of CPP and EP, and to explore the differences in the efficacy of different intervention timing. Methods: The medical information of girls with CPP or EP at a women’s and children’s hospital from January 2013 to December 2018 was retrospectively collected. The primary outcome of efficacy was final height, and the secondary outcome included height gain, genetic height gain, standard deviation score of final height (FHSDS), and standard deviation score of height (HSDS) gain. The safety outcomes were the rate of composite adverse event and the rate of each adverse event. The generalized linear model (GLM) including confounders as covariates was applied to compare the difference between the groups, and subgroup analysis was further performed to explore the efficacy with different timing of intervention. Results: A total of 182 girls with CPP or EP were finally included in this study. The adjusted results of GLM showed that the final height in the combination therapy group (162.58 ± 0.46 cm) was significantly higher than that in the monotherapy group (160.25 ± 0.35 cm) and the no treatment group (158.39 ± 0.47 cm) (P < 0.001), and the height gain, genetic height gain, FHSDS, and HSDS gain were all significantly different among the three groups (P < 0.001). Besides, the incidence of composite adverse events was greatly increasing in the combination therapy group (P < 0.001), among which the incidence of fasting insulin elevation and hypothyroidism was significantly higher than the other two groups (P < 0.001). Subgroup analysis showed that the girls who entered puberty after the age of 8 years (P = 0.051), initiated pharmacotherapy at the age of 10-12 years (P = 0.204, P = 0.178), treated with GnRHa for less than one year (P = 0.718), and combined with rhGH for less than one year (P = 0.064) may not improve the final height. Conclusions: The combination of GnRHa and rhGH can improve the final height of girls with CPP and EP to a certain extent, especially for those who began pharmacotherapy before 10 years of age and continued treatment for more than one year, but meanwhile increased the incidence of adverse events. The benefits, risks, and affordability of medication should still be comprehensively considered before the decisions on pharmacotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%